Experts Preview Key Abstracts to Watch at the 2026 Genitourinary Cancers Symposium

As anticipation builds for the 2026 Genitourinary (GU) Cancers Symposium, clinicians are preparing for a data-rich program expected to span the continuum of care across prostate, bladder, and kidney cancers. Jad Chahoud, MD, MPH, chief scientific and innovation officer at Orlando Health Cancer Institute; and Mehmet Bilen, MD, director of the GU Medical Oncology Program at the Winship Cancer Institute of Emory University, shared the abstracts they’re most anticipating during the meeting.

In prostate cancer specifically, experts are monitoring trials evaluating systemic intensification and radiopharmaceutical strategies earlier in the disease course, including the randomized phase 3 PEACE-2 study (NCT01952223) assessing androgen deprivation therapy (ADT) and radiotherapy with or without cabazitaxel in patients with very–high-risk localized disease. Furthermore, investigators will present additional quality-of-life data from the phase 3 PSMAddition trial (NCT04720157), which investigated the addition of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to standard-of-care therapy in patients with metastatic hormone-sensitive prostate cancer. Patient-reported outcome data from the phase 3 CAPItello-281 trial (NCT04493853) will also be shared; this study evaluated capivasertib (Truqap) plus abiraterone acetate (Zytiga) vs placebo plus abiraterone acetate in patients with PTEN-deficient mHSPC. Final overall survival data are also anticipated from the phase 3 EORTC 1333/PEACE-3 trial (NCT02194842) of enzalutamide (Xtandi) with or without radium-223 (Xofigo) in patients with metastatic castration-resistant prostate cancer with bone metastases.

In the kidney cancer space, data are anticipated from a pair of trials evaluating belzutifan (Welireg)-based combinations: the phase 3 LITESPARK-022 (NCT05239728) and LITESPARK-011 (NCT04586231) studies. LITESPARK-022 evaluated the addition of belzutifan to pembrolizumab (Keytruda) vs pembrolizumab plus placebo as adjuvant therapy in patients with high-risk clear cell renal cell carcinoma (RCC) following nephrectomy. It was previously announced that this study met its disease-free survival (DFS) primary end point. LITESPARK-011, which investigated belzutifan plus lenvatinib (Lenvima) vs cabozantinib (Cabometyx) monotherapy in patients with advanced RCC who have experienced disease progression on or after anti–PD-(L)1 therapy, also reached its progression-free survival primary end point, according to a prior news release.

Within the bladder cancer realm, Chahoud highlighted a presentation on the phase 3 KEYNOTE-905 trial (NCT03924895), which evaluated perioperative enfortumab vedotin-ejfv (Padcev) plus pembrolizumab in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for cisplatin-based chemotherapy. This analysis will focus on pathological and DFS outcomes after prior data supported the November 2025 FDA approval of this combination as neoadjuvant treatment followed by adjuvant treatment after cystectomy for patients with MIBC who are ineligible for cisplatin.